KIT is detected in a variety of cells, also in acute leukemia. Inhibition of wild-type KIT is not always satisfactory. The aim of this work was to evaluate the frequency of the most common KIT mutations in acute myeloid leukemia (AML) and determine the correlation between mutation and expression level. Samples were obtained from 75 patients with AL. CD117 presence was shown in 45 of 51 patients with AML and in 1 of 16 patients with acute lymphocytic leukemia (ALL). Asp816Val mutation was found in 3.5% of cases of AML and Val560Gly mutation in 1 sample with acute biclonal leukemia. Other genetic changes were found in 15 of 57 samples with AML: polymorphisms Met541Leu in 14% of cases, Lys546Lys in 7% and 1 case of acute biclonal leukemia, Ile798Ile in 5.3% of cases, Met541Leu in 1 acute biphenotypic leukemia and in 6.3% of ALL. Polymorphism Lys546Lys was also shown in 1 case of acute biclonal leukemia. Nonsilent genetic changes were detected in a total of 23% cases with core binding factor leukemia. There was no statistical significance between KIT expression and genetic changes. There was no correlation between the incidence and types of KIT mutations and its expression on cells in AML.

Keywords:
KIT, CD117, Proto-oncogene, Acute leukemia, Acute myeloid leukemia
1.
Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A: Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987;6:3341-3351.
2.
Giebel LB, Strunk KM, Holmes SA, Spritz RA: Organization and nucleotide sequence of the human KIT (mast/stem cell growth factor receptor) proto-oncogene. Oncogene 1992;7:2207-2217.
3.
Besmer P, Manova K, Duttlinger R, Huang EJ, Packer A, Gyssler C, Bachvarova RF: The kit-ligand (steel factor) and its receptor c-kit/W: pleiotropic roles in gametogenesis and melanogenesis. Dev Suppl 1993;125-137.
4.
Ashman LK, Cambareri AC, To LB, Levinsky RJ, Juttner CA: Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow. Blood 1991;78:30-37.
5.
Lammie A, Drobnjak M, Gerald W, Saad A, Cote R, Cordon-Cardo C: Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem 1994;42:1417-1425.
6.
Mayrhofer G, Gadd SJ, Spargo LD, Ashman LK: Specificity of a mouse monoclonal antibody raised against acute myeloid leukaemia cells for mast cells in human mucosal and connective tissues. Immunol Cell Biol 1987;65:241-250.
7.
Natali PG, Nicotra MR, Sures I, Santoro E, Bigotti A, Ullrich A: Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res 1992;52:6139-6143.
8.
Ogawa M, Matsuzaki Y, Nishikawa S, Hayashi S, Kunisada T, Sudo T, Kina T, Nakauchi H, Nishikawa S: Expression and function of c-kit in hemopoietic progenitor cells. J Exp Med 1991;174:63-71.
9.
Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-580.
10.
Nakata Y, Kimura A, Katoh O, Kawaishi K, Hyodo H, Abe K, Kuramoto A, Satow Y: c-kit point mutation of extracellular domain in patients with myeloproliferative disorders. Br J Haematol 1995;91:661-663.
11.
Gari M, Goodeve A, Wilson G, Winship P, Langabeer S, Linch D, Vandenberghe E, Peake I, Reilly J: C-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol 1999;105:894-900.
12.
Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y, Matzuzawa Y, Kitamura Y, Kanakura Y: Identification of mutations in the coding sequence of the proto-oncogene c-kit in human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993;92:1736-1744.
13.
Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S, Dimitrijevic S, Kononen J, Lugli A, Simon R, Sauter G: Prevalence of KIT expression in human tumors. J Clin Oncol 2004;22:4514-4522.
14.
Singer G, Schraml P, Belgard C, Raggi A, Dirnhofer S, Went P, Mihatsch MJ, Moch H: KIT in ovarian carcinoma: disillusion about a potential therapeutic target. J Natl Cancer Inst 2003;95:1009-1010.
15.
Lasota J, Wozniak A, Sarlomo-Rikala M, Rys J, Kordek R, Nassar A, Sobin LH, Miettinen M: Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 2000;157:1091-1095.
16.
Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA: KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-8121.
17.
Jaffe ES, Krenacs L, Kumar S, Kingma DW, Raffeld M: Extranodal peripheral T-cell and NK-cell neoplasms. Am J Clin Pathol 1999;111(suppl 1):S46-S55.
18.
Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, Metcalfe DD: Identification of a point mutation in the catalytic domain of the protooncogene c-KIT in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995;92:10560-10564.
19.
Longley BJ, Reguera MJ, Ma Y: Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 2001;25:571-576.
20.
Ning ZQ, Li J, Arceci RJ: Activating mutations of c-kit at codon 816 confer drug resistance in human leukemia cells. Leuk Lymphoma 2001;4:513-522.
21.
Meshinchi S, Stirewalt DL, Alonzo TA, Zhang Q, Sweetser DA, Woods WG, Bernstein ID, Arceci RJ, Radich JP: Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood 2003;102:1474-1479.
22.
Kindler T, Breitenbuecher F, Marx A, Beck J, Hess G, Weinkauf B, Duyster J, Peschel C, Kirkpatrick CJ, Theobald M, Gschaidmeier H, Huber C, Fischer T: Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood 2004;103:3644-3654.
23.
Szatkowski D, Lewandowski K, Prejzner W, Hellmann A: C-kit protooncogene expression on blastic cells in acute myeloid leukaemia. Acta Haematol Pol 2002;33:431-441.
24.
Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302.
25.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451-458.
26.
Rothe G, Schmitz G: Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Leukemia 1996;10:877-895.
27.
Tsao AS, Kantarjian H, Thomas D, Giles F, Cortes J, Garcia-Manero G, Huh Y, Yang Y, Shen Y, Albitar M, Estey E: C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome. Leuk Res 2004;28:373-378.
28.
Valverde LR, Matutes E, Farahat N, Heffernan A, Owusu-Ankomah K, Morilla R, Catovsky D: C-kit receptor (CD117) expression in acute leukemia. Ann Hematol 1996;72:11-15.
29.
Reuss-Borst MA, Buhring HJ, Schmidt H, Muller CA: AML: immunophenotypic heterogeneity and prognostic significance of c-kit expression. Leukemia 1994;8:258-263.
30.
Ashman LK, Roberts MM, Gadd SJ, Cooper SJ, Juttner CA: Expression of a 150-kD cell surface antigen identified by monoclonal antibody YB5.B8 is associated with poor prognosis in acute non-lymphoblastic leukaemia. Leuk Res 1988;12:923-928.
31.
Auewarakul CU, Lauhakirti D, Promsuwicha O, Munkhetvit C: C-kit receptor tyrosine kinase (CD117) expression and its positive predictive value for the diagnosis of Thai adult acute myeloid leukemia. Ann Hematol 2006;85:108-112.
32.
Bene MC, Bernier M, Casasnovas RO, Castoldi G, Knapp W, Lanza F, Ludwig WD, Matutes E, Orfao A, Sperling C, van't Veer MB: The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. Blood 1998;92:596-599.
33.
Cascavilla N, Musto P, D'Arena G, Melillo L, Carella AM, Petrilli M, Sanpaolo G, Carotenuo M: CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype. Haematologica 1998;83:392-397.
34.
Muroi K, Suda T, Kawano C, Amemiya Y, Eguchi M, Miura Y, Ozawa K: Analysis of C-KIT, TIE and HTK expression on leukemic cells using flow cytometry: a preliminary report. Leukemia Res 1998;22:827-830.
35.
Sperling C, Schwartz S, Buchner T, Thiel E, Ludwig WD: Expression of the stem cell factor receptor (CD117) in acute leukemias. Haematologica 1997;82:617-621.
36.
Buttner C, Henz BM, Welker P, Sepp NT, Grabbe J: Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J Invest Dermatol 1998;111:1227-1231.
37.
Kanakura Y, Furitsu T, Tsujimura T, Butterfield JH, Ashman LK, Ikeda H, Kitayama H, Kanayama Y, Matsuzawa Y, Kitamura Y: Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line. Leukemia 1994;8(suppl 1):S18-S22.
38.
Hou YY, Tan YS, Sun MH, Wei YK, Xu JF, Lu SH, A-Ke-Su SJ, Zhou YN, Gao F, Zheng AH, Zhang TM, Hou WZ, Wang J, Du X, Zhu XZ: C-kit gene mutation in human gastrointestinal stromal tumors. World J Gastroenterol 2004;10:1310-1314.
39.
Morey AL, Wanigesekera GD, Hawkins NJ, Ward RL: C-kit mutations in gastrointestinal stromal tumours. Pathology 2002;34:315-319.
40.
Riva P, Larizza L: A novel potentially diagnostic polymorphism (4894 A/C) in exon 10 of the human c-kit proto-oncogene. Mol Cell Probes 1996;10:387-388.
41.
Shibanuma K, Tong ZB, Vanderhoof VH, Vanevski K, Nelson LM: Investigation of KIT gene mutations in women with 46,XX spontaneous premature ovarian failure. BMC Womens Health 2002;2:8.
42.
Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ: Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood 2000;96:925-931.
43.
Hu S, Niu H, Minkin P, Orwick S, Shimada A, Inaba H, Dahl GV, Rubnitz J, Baker SD: Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. Mol Cancer Ther 2008;7:1110-1120.
44.
Guerrouahen BS, Futami M, Vaklavas C, Kanerva J, Whichard ZL, Nwawka K, Blanchard EG, Lee FY, Robinson LJ, Arceci R, Kornblau SM, Wieder E, Cayre YE, Corey SJ: Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res 2010;16:1149-1158.
45.
Kindler T, Breitenbuecher F, Marx A, Hess G, Gschaidmeier H, Gamm H, Kirkpatrick CJ, Huber C, Fischer T: Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML. Blood 2003;101:2960-2962.
46.
Nanri T, Matsuno N, Kawakita T, Mitsuya H, Asou N: Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation. Leukemia 2005;19:1673-1675.
47.
Cortes J, Giles F, O'Brien S, Thomas D, Albitar M, Rios MB, Talpaz M, Garcia-Manero G, Faderl S, Letvak L, Salvado A, Kantarjian H: Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer 2003;97:2760-2766.
48.
Heidel F, Cortes J, Rücker FG, Aulitzky W, Letvak L, Kindler T, Huber C, Döhner H, Kantarjian H, Fischer T: Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and imatinib. Cancer 2007;109:907-914.
49.
Crump M, Hedley D, Kamel-Reid S, Leber B, Wells R, Brandwein J, Buckstein R, Kassis J, Minden M, Matthews J, Robinson S, Turner R, McIntosh L, Eisenhauer E, Seymour L: A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC Clinical Trials Group Study. Leuk Lymphoma 2010;51:252-260.
50.
Fiedler W, Mesters R, Heuser M, Ehninger G, Berdel WE, Zirrgiebel U, Robertson JD, Puchalski TA, Collins B, Jürgensmeier JM, Serve H: An open-label, phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia. Leuk Res 2010;34:196-202.
51.
Frost MJ, Ferrao PT, Hughes TP, Ashman LK: Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 2002;1:1115-1124.
52.
Schittenhelm M, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006;66:473-481.
53.
Verstovsek S, Akin C, Manshouri T, Quintás-Cardama A, Huynh L, Manley P, Tefferi A, Cortes J, Giles FJ, Kantarjian H: Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res 2006;30:1365-1370.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.